Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Myocardial-Infarction"

16 News Found

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
Drug Approval | November 08, 2023

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India


Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules
Drug Approval | April 24, 2023

Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules

Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels


SRL Diagnostics launches ‘Heart Assure Test’ to predict risk of cardiac event
Healthcare | September 28, 2022

SRL Diagnostics launches ‘Heart Assure Test’ to predict risk of cardiac event

Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup


Rivaroxaban approved in Japan for patients with PAD after revascularisation
Drug Approval | June 24, 2022

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition


Gut microbiome as a tool in regenerative medicine
Biotech | May 07, 2022

Gut microbiome as a tool in regenerative medicine

Novel approach driven by GN Corp Japan with potentials in neurological illnesses


Pfizer voluntary recall of drugs in the US
News | March 23, 2022

Pfizer voluntary recall of drugs in the US

Voluntary nationwide recall of lots of Accuretic (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to n-nitroso- quinapril content